Neuralstem Receives Buy Rating from Aegis (CUR)
Shares of Neuralstem (NYSE:CUR) traded up 8.91% during mid-day trading on Friday, hitting $3.30. 773,411 shares of the company’s stock traded hands. Neuralstem has a 1-year low of $1.43 and a 1-year high of $4.81. The stock has a 50-day moving average of $3.5 and a 200-day moving average of $3.71. The company’s market cap is $286.3 million.
Neuralstem (NYSE:CUR) last posted its quarterly earnings results on Friday, August 8th. The company reported ($0.08) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.05) by $0.03. Analysts expect that Neuralstem will post $-0.25 EPS for the current fiscal year.
Neuralstem, Inc is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.